-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EPI-005 in Post-Traumatic Stress Disorder (PTSD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EPI-005 in Post-Traumatic Stress Disorder (PTSD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EPI-005 in Post-Traumatic Stress Disorder (PTSD) Drug Details: EPI-005...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EPI-589 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EPI-589 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EPI-589 in Parkinson's Disease Drug Details: EPI-589 (PTC-589) is under development for...
-
Product Insights
NewEpigenomics AG Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Epigenomics AG Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Masofaniten in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masofaniten in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masofaniten in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Masofaniten...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vatiquinone in Friedreich Ataxia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vatiquinone in Friedreich Ataxia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vatiquinone in Friedreich Ataxia Drug Details: Vatiquinone (EPI-743) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vatiquinone in Subacute Necrotizing Encephalomyelopathy (Leigh Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vatiquinone in Subacute Necrotizing Encephalomyelopathy (Leigh Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vatiquinone in Subacute Necrotizing Encephalomyelopathy (Leigh Disease) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vatiquinone in MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vatiquinone in MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vatiquinone in MELAS Syndrome...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vatiquinone in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vatiquinone in Epilepsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vatiquinone in Epilepsy Drug Details: Vatiquinone (EPI-743) is under development for the...
-
Company Insights
NewiDEAL – Competitor Profile
iDEAL - a market leader in Dutch third-party payment services—was established by payment systems provider Currence in 2005. iDEAL offers online payments for Dutch domestic and international shoppers, enabling them to pay for online purchases directly from their bank accounts. iDEAL also enables consumers to carry out other transactions such as utility bill payments, mobile top-ups, and donations. It generates business by offering five types of transactions: domestic ecommerce payments, cross-border ecommerce payments, payments between consumers, non-ecommerce payments, and buy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VMD-928 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VMD-928 in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VMD-928 in Colon Cancer Drug Details: VMD-928 is under development for...